Belite Bio (BLTE) Cash from Financing Activities (2024 - 2025)

Belite Bio (BLTE) recorded quarterly Cash from Financing Activities of $510.1 million in Q4 2025, up 1182.51% quarter-over-quarter from $39.8 million in Q4 2024, and up 1182.51% on a YoY basis from $39.8 million in Q4 2024.

Belite Bio (BLTE) Cash from Financing Activities (2024 - 2025) Analysis & Trends

Belite Bio's Cash from Financing Activities history runs 2 years deep, the most recent figure standing at $510.1 million for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 7.00 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -600,000.00
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 53,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -538.80 Mn
9 Abivax 91.96 Bn 91.96 Bn - 85,464.43
10 Regeneron Pharmaceuticals 63.43 Bn 54.67 Bn 3.31 Bn -802.20 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 510.12 Mn
Dec 31, 2025 510.12 Mn
Dec 31, 2024 39.78 Mn
Dec 31, 2024 39.78 Mn